Pan tumor
Conditions
Brief summary
Incidence of adverse events (including related AEs, AEs leading to discontinuation, SAEs, select AEs, immune-mediated AEs, and deaths).
Detailed description
OS defined as date of randomization, first dose, or as defined in the Parent Study until date of death from any cause or censored on the last known alive date in the rollover study, Incidence of AEs.
Interventions
DRUGALIMTA 500 mg powder for concentrate for solution for infusion
DRUGDARATUMUMAB
DRUGTEMOZOLOMIDE
DRUGRUCAPARIB
DRUGBEVACIZUMAB
DRUGOPDIVO 10 mg/mL concentrate for solution for infusion.
DRUGAvastin 25 mg/ml concentrate for solution for infusion.
DRUGOXALIPLATIN
DRUGSutent 37.5 mg hard capsules
DRUGSUNITINIB
DRUGTRAMETINIB
DRUGFLUOROURACIL
DRUGPEMETREXED
DRUGYERVOY 5 mg/ml concentrate for solution for infusion
DRUGRelatlimab
DRUGKEYTRUDA 25 mg/mL concentrate for solution for infusion
DRUGPEMBROLIZUMAB
DRUGCAPECITABINE
DRUGCABOZANTINIB
DRUGSodiofolin 50 mg/ml
DRUGsolution for injection/infusion
DRUGENZALUTAMIDE
DRUGREGORAFENIB
Sponsors
Bristol-Myers Squibb Services Unlimited Company
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of adverse events (including related AEs, AEs leading to discontinuation, SAEs, select AEs, immune-mediated AEs, and deaths). | — |
Secondary
| Measure | Time frame |
|---|---|
| OS defined as date of randomization, first dose, or as defined in the Parent Study until date of death from any cause or censored on the last known alive date in the rollover study, Incidence of AEs. | — |
Countries
Austria, Belgium, Czechia, France, Germany, Greece, Italy, Poland, Romania, Spain
Outcome results
None listed